SEARCH

SEARCH BY CITATION

References

  • 1
    Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010;65(Suppl. 2):ii510.
  • 2
    Tamiflu Prescribing Information. Tamiflu® (oseltamivir) prescribing information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name (last accessed on 25 August 2010).
  • 3
    Tamiflu Summary of Product Characteristics. http://emc.medicines.org.uk/. 2009 (last accessed on 25 August 2010).
  • 4
    Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31:1097114.
  • 5
    Goshima N, Nakano T, Nagao M, Ihara T. A clinical study of abnormal behaviors in patients with influenza. Infect Immun Child 2006;18:3716.
  • 6
    Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 2006;25:572.
  • 7
    Fujita T, Mori M, Okumura A, Hosoya M, Suzuki H, Morishima T et al. Epidemiologic survey of influenza-associated complications II. A statistical analysis of symptoms and signs, and medication. J Jpn Pediatr Soc 2007;111:2.
  • 8
    Hirota Y. Survey Research on the Emergence of Influenza-Associated Symptoms. 2007/2008 Research Subteam Report. MHLW Scientific Research Fund, Tokyo, Japan, 2009.
  • 9
    Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med 2007;9:23.
  • 10
    Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009;21:7989.
  • 11
    Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009;63:596605.
  • 12
    Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009;53:475361.
  • 13
    Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008;52:368793.
  • 14
    Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and active metabolite. Eur J Pharmacol 2010;628:610.
  • 15
    Mahowald MW. Parasomnias. Med Clin North Am 2004;88:66978.
  • 16
    Sateia MJ. Update on sleep and psychiatric disorders. Chest 2009;135:13709.
  • 17
    Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Satges in Human Subjects. University of California Brain Information Service, Los Angeles, CA, 1968.
  • 18
    Atlas Task Force of the American Sleep Disorders Association. EEG arousals: scoring rules and examples. Sleep 1992;15:17484.
  • 19
    Bornemann MA, Mahowald MW, Schenck CH. Parasomnias: clinical features and forensic implications. Chest 2006;130:60510.
  • 20
    Schenck CH, Lee SA, Bornemann MA, Mahowald MW. Potentially lethal behaviors associated with rapid eye movement sleep behavior disorder: review of the literature and forensic implications. J Forensic Sci 2009;54:147584.
  • 21
    Cartwright R. Sleepwalking violence: a sleep disorder, a legal dilemma, and a psychological challenge. Am J Psychiatry 2004;161:114958.
  • 22
    Ding M, Toth LA. mRNA expression in mouse hypothalamus and basal forebrain during influenza infection: a novel model for sleep regulation. Physiol Genomics 2006;24:22534.
  • 23
    Majde JA, Kapas L, Bohnet SG, De A, Krueger JM. Attenuation of the influenza virus sickness behavior in mice deficient in Toll-like receptor 3. Brain Behav Immun 2010;24:30615.
  • 24
    Arnulf I, Zeitzer JM, File J, Farber N, Mignot E. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain Dev 2005;128:276376.
  • 25
    Fukumoto Y, Okumura A, Hayakawa F, Suzuki M, Kato T, Watanabe K et al. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev 2007;29:42530.
  • 26
    Okumura A, Nakano T, Fukumoto Y, Higuchi K, Kamiya H, Watanabe K et al. Delirious behavior in children with influenza: its clinical features and EEG findings. Brain Dev 2005;27:2714.
  • 27
    Huang YC, Lin TY, Wu SL, Tsao KC. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr Infect Dis J 2003;22:3668.
  • 28
    Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 2007;334:12323.
  • 29
    Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003;26:787801.
  • 30
    Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007;47:68996.
  • 31
    Fuke C, Ihama Y, Miyazaki T. Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu((R)). Leg Med (Tokyo) 2008;10:837.
  • 32
    Straumanis JP, Tapia MD, King JC. Influenza B infection associated with encephalitis: treatment with oseltamivir. Pediatr Infect Dis J 2002;21:1735.